Cipla unhappy with certain Patent Pool conditions

Cipla has expressed reservations over certain key components of licensing terms with the Medicines Patent Pool, which recently signed its first licence agreement with Gilead Sciences for five products for the treatment of HIV and hepatitis B.

In response to a specific query from Scrip following the Indian firm's annual general meeting in Mumbai, Cipla's chairman, Dr...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Novartis’s Cosentyx Suffers Rare Phase III Fail

03 Jul 2025

• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

03 Jul 2025

• By Sushmita Panda

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.